Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TQH2929 Injection for acute flares of generalized pustular psoriasis
CTR20255039Phase 2Terminated
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH2929 in generalized pustular psoriasis (GPP), sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2026; status: terminated.
02
Drugs
TQH2929
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20255039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255039.